- In patients with locally advanced basal cell carcinoma (LA-BCC) who discontinued vismodegib and relapsed, retreatment is associated with an 85% objective response rate, according to a retrospective study.
Why this matters
- Adverse events associated with vismodegib often lead to discontinuation.
- Median relapse-free survival (RFS) of patients who discontinued vismodegib was 18.4 (95% CI, 13.5-24.8) months; 36-month RFS was 35.4% (95% CI, 22.5%-47.9%).
- Limb/trunk BCC was associated with increased risk for relapse (HR, 2.77; P=.019).
- 50% of patients who experienced relapse were retreated with vismodegib, with an objective response rate of 85% (37% complete response, 48% partial response) and eligibility for surgery in 42%.
- 116 patients with LA-BCC who originally experienced a complete response with vismodegib but then discontinued were analyzed for RFS and effects of subsequent treatment.
- 27 patients who experienced relapse were retreated with vismodegib.
- Funding: Roche Laboratories.
- Retrospective study design.
- Small patient sample size.